With the growing understanding of human biology, along with increased availability of innovative technologies, there is now an unprecedented opportunity to translate scientific discoveries into new, more effective, and safer health interventions. Organ-on-a-chip is an innovative, alternative approach that would enable early indications and potentially more reliable readouts of toxicity and efficacy for biological product testing. It recapitulates the multicellular architectures, tissue-tissue interfaces and physicochemical microenvironments.
It may also enable vascular perfusion and innervation, producing in essence microphysiological systems that mimic human tissue and organ functionality not possible with conventional
2D or 3D culture systems. In the context of new speciality chemicals, ingredients and cosmetic formulations development and drug discovery, it is valuable for the investigation of molecular mechanisms, prioritisation of lead candidates, toxicity testing, and biomarker identification. It has also proven to be a useful and powerful tool for modelling human diseases.
This MasterClass will touch on ongoing efforts and various applications of organ-on-a-chip technologies in advanced biological product testing. The MasterClass will provide participants from industries, government laboratories, and academia, with a state-of-the-art overview and analysis of organ-on-a-chip technologies. The course will be conducted by international leaders in organ-on-a-chip research, innovation, and commercialisation.
No prior knowledge in organ-on-a-chip is required.
The MasterClass will introduce the development and testing process of new biological products, including preclinical trials, animal trials, and human clinical trials. Participants learn about the emerging application of organ-on-a-chip technologies for biological product testing and understand the role of microscale system in cosmetic, chemicals, pharmaceutical and food ingredient testing. The MasterClass will also highlight the opportunities and translational challenges for the commercialisation of organ-on-a-chip technologies through case studies from the invited speakers’ first-hand experiences.